

# Investor Report

30 April 2024

## Geiger Counter Limited

### Key Fund Facts<sup>1</sup>

Fund Managers	Keith Watson Robert Crayford
Launch Date	July 2006
Total Gross Assets	£107.1m
Reference Currency	GBP
Ordinary Shares	Net Asset Value: 72.33p Diluted Net Asset Value 67.99p (assuming all subscription rights are exercised) Mid-Market Price: 54.30p
Gearing	17.47%
Premium / (Discount) to NAV	(24.93%)
Premium / (Discount) to Diluted NAV	(20.14%)
Ordinary Shares in Issue	126,069,708
Annual Management Fee	1.38%
Bloomberg	GCL LN
Sedol	B15FW330
Year End	30 September
Contact Information	<a href="mailto:contactncim@cqsm.com">contactncim@cqsm.com</a>
Company Broker	Cavendish Capital Markets Limited 020 7220 0500
Annual Report and Accounts Published	December
Investor Report	Monthly Factsheet
Fiscal Year-End	30 September
Results Announced	Finals: December Interims: June

Sources: <sup>1</sup>R&H Fund Services (Jersey) Limited, as at the last business day of the month indicated at the top of this report. <sup>2</sup>R&H Fund Services Limited/DataStream, as at the last business day of the month indicated at the top of this report, total return performance net of fees and expenses based on bid prices. These include historic returns and past performance is not a reliable indicator of future results. The value of investments can go down as well as up. Please read the important legal notice at the end of this document. <sup>3</sup>Market data sourced from Bloomberg unless otherwise stated. The Fund may since have exited some or all of the positions detailed in the commentary.



**Keith Watson and Robert Crayford**  
Portfolio Managers

### Fund Description

The objective of the Geiger Counter Fund is to provide investors with the potential for capital growth through investment primarily in the securities of companies involved in the exploration, development and production of energy, predominantly within the uranium industry. Up to 30% of the value of the Company's investment portfolio may be invested in other resource-related companies from outside the energy sector.

### Key Advantages for the Investor

- Access to mining assets in the uranium sector
- May benefit from embedded subscription share
- Low correlation to major asset classes

### Ordinary Share and NAV Performance<sup>2</sup>

	1 Month (%)	3 Months (%)	1 Year (%)	3 Years (%)	5 Years (%)
NAV	1.44	(7.72)	84.61	100.08	290.76
Share Price	8.60	(12.42)	46.76	45.19	188.83

### Commentary<sup>3</sup>

The spot U<sub>3</sub>O<sub>8</sub> was little changed in April, closing the month at \$89/lb. Uranium mining equities showed slight improvement following the prior month's consolidation. The Fund NAV rose 1.4% versus a 3.4% sterling gain registered by the Solactive Uranium Pure Play Index.

One of the prime detractors to performance was Energy Fuels, whose share price declined over 14% in sterling terms following its A\$341m all-share offer to acquire mineral sands producer and developer Base Resources with a view to processing monazite (which contains both uranium and rare earth elements) at its White Mesa mill in the US.

Nexgen ended the month around 1.0% lower in sterling terms as the group issued A\$250m shares at an effective 4.8% discount, providing the group with a secondary ASX-listing to take advantage of relative valuation differentials compared to their ASX-listed peers. Offsetting these declines, Fission and Ur-Energy made useful positive contributions with sterling share price rises of over 10% and 5% respectively.

In the run-up to the Trust's issue of embedded shareholder rights, broader sector news remains encouraging. Kazakh floods, caused by meltwater from a sudden spring thaw, helped support the uranium market and briefly lifted uranium mining equities. The floods occurred on the river systems in the west and northwest and away from southerly mine operations meaning the extent of disruption is expected to be limited. However, the event nevertheless illustrates supply vulnerabilities from the region (currently responsible for ~40% of global mined uranium), a far less discussed risk.

Before the floods, state-owned Kazatomprom's Q1 results disappointed with attributable production and group sales some 5% and 30% below market expectations. The company did however maintain its full-year guidance for attributable production of 28.3-30.9Mlb U<sub>3</sub>O<sub>8</sub> at a cash cost of US\$16.5-18.0/lb. However, it is worth noting that recent record on guidance has been optimistic.

Elsewhere, China National Nuclear Power Corporation provided 2024 investment targets indicating a +52% year-on-year increase. With 15 reactors currently already under construction, China's total nuclear power generation capacity is on track to exceed 100GW before the end of the decade, with the region overtaking the US as the largest nuclear power market.

India Atomic Energy Commission announced plans to expand nuclear output to 100GW by 2047, from around 8GW today. While extremely ambitious, it indicates the potential growth in nuclear in emerging economies.

(continued on the next page)

## Commentary<sup>1</sup>

In the US, PSEG Nuclear, which runs three nuclear power plants in New Jersey, announced intentions to seek federal approval for 20-year life extensions. This allows the plants to run beyond 2050 and is in keeping with recent moves by utilities in established nuclear power markets.

More significant for the continued positive sector outlook was news released just after the month-end that the US Senate passed a bill limiting Russian enriched uranium imports into the country. While the act has several waivers in place until 2027 to help ease the initial impact on the US (which generates approximately 19% of its electricity from nuclear power) possible consequences include increased uranium requirements from European-owned enrichment facilities. The act could prompt them to “overfeed” facilities, effectively processing greater quantities of U<sub>3</sub>O<sub>8</sub> for a shorter period to obtain necessary fuel grade product, thus increasing demand for U<sub>3</sub>O<sub>8</sub> and conversion. If a full export ban is enacted, there could be more urgency for utilities to secure long-term supply contracts as well as the potential for trade retaliation from Russia, both of which could put additional pressure on requirements in the near-term. This bill followed the release of a survey by consultancy UxC that indicated the need for more western enrichment and conversion capacity (crucial steps in the nuclear fuel supply chain) and significant new incremental conversion capacity will come online between 2028-29.

## AIFMD Leverage Limit Report (% NAV)

	Gross Leverage (%) <sup>2</sup>	Commitment Leverage (%) <sup>3</sup>
Geiger Counter Limited	118	118

## Top 5 Holdings (%)<sup>4</sup>

Name	(% of Gross Assets)
Nexgen Energy	24.3%
UR-Energy	13.0%
Paladin Energy	10.2%
Cameco	8.2%
Uranium Energy	8.1%
<b>Top 5 Holdings Represent</b>	<b>63.8</b>

## Company Update

The Company has announced the results of the 2024 Subscription Rights Exercise. There is a cap of Euro 8 million on the total value the Company can raise from the exercise. There was a scaling back exercise done on the basis that all shareholders are scaled back pro-rata to their Subscription Rights, whether or not they have sought to exercise such Subscription Rights. The scaling back factor means that all shareholders received 70.96% of their entitlement.

On 7 May 2024, 12,314,071 new shares were issued at a price of 37.74p each as a result of applications received from shareholders. On 9 May 2024 a further 5,816,025 new shares were placed into the market at a price of 51.0p per share – of that amount 37.74p per share was credited to Geiger Counter Limited with the difference of approximately 13p per share (on the scaled back calculation) being credited to those shareholders who did not take up their subscription rights.

The Company has also announced the fourth Subscription Rights Price of 74.58 pence on 1 May 2024. The exercise date for the third Subscription Right is expected to be 30 April 2025.

Sources: <sup>1</sup>Market data sourced from Bloomberg unless otherwise stated. The Fund may since have exited some or all of the positions detailed in the commentary. <sup>2</sup>CQS, as at the last business day of the month indicated at the top of this report. For methodology details see Article 4(3) of Directive 2011/61/EU (AIFMD) and Articles 6, 7, 9 and 10 of Delegated Regulation 231/2013. <sup>3</sup>CQS, as at the last business day of the month indicated at the top of this report. For methodology details see Article 4(3) of Directive 2011/61/EU (AIFMD) and Articles 6, 8, 9, 10 and 11 of Delegated Regulation 231/2013. <sup>4</sup>R&H Fund Services (Jersey) Limited, as at the last business day of the month indicated at the top of this report. All holdings data are rounded to one decimal place. Total may differ to sum of constituents due to rounding.

**Important Information**

Manulife | CQS Investment Management is a trading name of CQS (UK) LLP which is authorised and regulated by the Financial Conduct Authority. This document has been issued by CQS (UK) LLP and/or CQS (US), LLC which is a registered investment adviser with the US Securities and Exchange Commission, The term “CQS” or “Manulife | CQS Investment Management” as used herein may include one or more of CQS (UK) LLP, CQS (US), LLC or any other affiliated entity. The information is intended solely for sophisticated investors who are (a) professional investors as defined in Article 4 of the European Directive 2011/61/EU or (b) accredited investors (within the meaning given to such term in Regulation D under the U.S. Securities Act of 1933, as amended) and qualified purchasers (within the meaning given to such term in Section 2(a)(51) of the U.S Investment Company Act 1940, as amended). This document is not intended for distribution to, or use by, the public or any person or entity in any jurisdiction where such use is prohibited by law or regulation.

Manulife | CQS Investment Management is a wholly owned subsidiary of Manulife Investment Management (Europe) Limited.

This document is a marketing communication prepared for general information purposes only and has not been delivered for registration in any jurisdiction nor has its content been reviewed by any regulatory authority in any jurisdiction. The information contained herein does not constitute: (i) a binding legal agreement; (ii) legal, regulatory, tax, accounting or other advice; (iii) an offer, recommendation or solicitation to buy or sell shares or interests in any fund or investment vehicle managed or advised by CQS (a “CQS Fund”) or any other security, commodity, financial instrument, or derivative; or (iv) an offer to enter into any other transaction whatsoever (each a “Transaction”). Any decision to enter into a Transaction should be based on your own independent investigation of the Transaction and appraisal of the risks, benefits and appropriateness of such Transaction in light of your circumstances. Any decision to enter into any Transaction should be based on the terms described in the relevant offering memorandum, prospectus or similar offering document, subscription document, key investor information document (where applicable), and constitutional documents and/or any other relevant document as appropriate (together, the “Offering Documents”). Any Transaction will be subject to the terms set out in the Offering Documents and all applicable laws and regulations. The Offering Documents supersede this document and any information contained herein. The Offering Documents for CQS UCITS range of funds is available [here](https://www.cqs.com/ucits-funds#global-convertibles) (https://www.cqs.com/ucits-funds#global-convertibles) in English (US persons will not be eligible to invest in CQS managed UCITS funds save to the extent set out in the relevant Offering Document). A copy of CQS’ Complaints Policy, which sets out a summary of investors’ rights, is available [here](http://www.cqs.com/site-services/regulatory-disclosures) (www.cqs.com/site-services/regulatory-disclosures) in English. CQS may terminate the arrangements for marketing or distribution of any CQS Fund at any time.

Nothing contained herein shall give rise to a partnership, joint venture or any fiduciary or equitable duties. The information contained herein is provided on a non-reliance basis, not warranted as to completeness or accuracy, and is subject to change without notice. Any information contained herein relating to any non-affiliated third party is the sole responsibility of such third party and has not been independently verified by CQS. The accuracy of data from third party vendors is not guaranteed. If such information is not

accurate, some of the conclusions reached or statements made may be adversely affected. CQS is not liable for any decisions made or action taken by you or others based on the contents of this document and neither CQS nor any of its directors, officers, employees or representatives accept any liability whatsoever for any errors or omissions or any loss howsoever arising from the use of this document.

**Information contained in this document should not be viewed as indicative of future results as past performance of any Transaction is not indicative of future results. Any investment in a CQS Fund or any of its affiliates involves a high degree of risk, including the risk of loss of the entire amount invested. The value of investments can go down as well as up. Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong.** Future performance is subject to taxation which depends on the personal situation of each investor and which may change in the future. Investments may lead to a financial loss if no guarantee on the capital is in place. An investment in any CQS Fund will involve a number of material risks which include, without limitation, risks associated with adverse market developments, currency and exchange rate risks, risk of counterparty or issuer default, and risk of illiquidity. Any assumptions, assessments, targets (including target returns and volatility targets), statements or other such views expressed herein (collectively “Statements”) regarding future events and circumstances or that are forward looking in nature constitute CQS’ subjective views or beliefs and involve inherent risk and uncertainties beyond CQS’ control. Any indices included in this document are for illustrative purposes only and are not representative of CQS Funds in terms of either composition or risk (including volatility and other risk related factors). Unless stated to the contrary CQS Funds are not managed to a specific index.

The information contained herein is confidential and may be legally privileged and is intended for the exclusive use of the intended recipient(s) to which the document has been provided. In accepting receipt of the information transmitted you agree that you and/or your affiliates, partners, directors, officers and employees, as applicable, will keep all information strictly confidential. Any review, retransmission, dissemination or other use of, or taking of any action in reliance upon, this information is prohibited. Any distribution or reproduction of this document is not authorized and prohibited without the express written consent of CQS, or any of its affiliates. Unless otherwise stated to the contrary herein, CQS owns all intellectual property rights in this document.

CQS is a founder of the Standards Board for Alternative Investments (“SBAI”) which was formed to act as custodian of the alternative investment managers’ industry best practice standards (the “Standards”). By applying the Standards, managers commit to adopt the “comply or explain” approach described in the Standards. CQS is a signatory of the UN Principles for Responsible Investment and a supporter and participant of certain other responsible investment related industry associations.

**PRI Note:**

PRI is an investor initiative in partnership with UNEP Finance and the UN Global Compact. GMv11.



G1179366 / 05.24

**CQS (UK) LLP**

4th Floor, One Strand, London WC2N 5HR, United Kingdom  
T: +44 (0) 20 7201 6900 | F: +44 (0) 20 7201 1200

**CQS (US), LLC**

152 West 57th Street, 40th Floor, New York, NY 10019, US  
T: +1 212 259 2900 | F: +1 212 259 2699

✉ CQSClientServices@cqsm.com     www.cqs.com     Follow us

Signatory of:

